Royalty Pharma (RPRX) Expected to Announce Earnings on Thursday

Royalty Pharma (NASDAQ:RPRX) is expected to be releasing its earnings data before the market opens on Thursday, February 20th. Analysts expect Royalty Pharma to post earnings of $1.09 per share and revenue of $743.60 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 50.53% and a return on equity of 24.65%. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Royalty Pharma Trading Up 1.5 %

RPRX stock opened at $32.85 on Wednesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The company’s 50-day simple moving average is $28.70 and its 200 day simple moving average is $27.82. Royalty Pharma has a 52 week low of $24.05 and a 52 week high of $32.89. The company has a market capitalization of $19.35 billion, a PE ratio of 17.02 and a beta of 0.49.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.68%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. Royalty Pharma’s dividend payout ratio is presently 43.52%.

Analysts Set New Price Targets

RPRX has been the topic of a number of analyst reports. Citigroup reduced their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. Finally, StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.